Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogen adhesion sites on mucosal surfaces refer to molecular structures, most commonly specific glycoproteins (such as mucins), oligosaccharide residues, or occasionally membrane proteins, displayed on the apical surfaces of mucosal epithelial cells that serve as binding sites for pathogenic microorganisms. These sites are critical for the initial step of infection, since many pathogens require attachment to the epithelium to colonize, evade clearance, or invade underlying tissues. The composition and glycosylation patterns of mucosal surfaces determine susceptibility to specific infections and are under dynamic regulation by both host factors and the resident microbiota. Multiple pathogens have evolved adhesin proteins that recognize and bind to these sites; disruption or modification of these adhesion processes is a key strategy for anti-infective therapeutics and mucosal vaccine development.
Blocking pathogen-host adhesion (anti-adhesion therapy), enhancing competitive exclusion via probiotics, antibody-mediated agglutination
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogen adhesion sites on mucosal surfaces.